A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work. The study compares two groups of participants who are confirmed to have mild-to moderated COVID-19 and who have high chances of the disease becoming severe. The two groups are: People who took the antiviral medication nirmatrelvir-ritonavir (also called Paxlovid) People who were eligible to receive antiviral medication but did not receive any. The participants will be selected from various health databases in the US between June 2021 and December 2022. The main goals are: To look at the characteristics of both groups of participants with COVID-19. To measure how much work these participants missed, including days off and sick leave, and the costs associated with this work loss. To compare work loss and costs between the two groups of participants, considering differences in their clinical and demographic characteristics. The study will evaluate at least 30 days of data from participants after they are confirmed to have COVID-19

NCT Number	NCT07072793
Lead Sponsor	Pfizer
Conditions	COVID-19 (Coronavirus Disease 2019)
Enrollment	131,005 participants
Start Date	2024-10-31
Primary Completion	2024-11-15 (estimated)
Study Completion	2024-11-15 (estimated)
Updated on ClinicalTrials.gov	2026-02-09